Skip to content

MDMA modulates human sensorimotor cortical pathways during gentle touch.

Hanna Molla, Giovanni Novembre, Anya K. Bershad, Linda Handlin, Irene Perini, Harriet de Wit, India Morrison

Imaging Neuroscience 2024 DOI: 10.1162/imag_a_00316 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Double-blind Peer reviewed
Sample size 18
Population Healthy participants
Interventions MDMA lactose placebo
Dose 1.5 mg/kg
Topics MDMA
Keywords Affective touch FMRI Oxytocin Social touch
Key findings MDMA enhances affective ratings of touch and increases plasma oxytocin levels, with greater hemodynamic changes in primary sensorimotor areas for both touch speeds.

Abstract

The stimulant ± 3,4-methylenedioxymethamphetamine (MDMA) has been shown to enhance the perceived pleasantness of touch. However, the underlying neural processes contributing to touch-related effects of MDMA are not well understood. Using a double-blind, randomized, within-subject design, this study used fMRI to examine hemodynamic changes following MDMA (1.5 mg/kg) vs. lactose placebo administration during gentle touch stimulation in a healthy sample (N= 18). Participants were stroked on the forearm at a slower, more pleasant (3 cm/s), and a faster (30 cm/s), less pleasant speed. For the MDMA session, participants' affective ratings of touch stimulation were higher than their placebo ratings. Increase in plasma oxytocin (OT) levels was also greater during the MDMA session. On the neural level, primary sensorimotor areas showed greater hemodynamic changes during the MDMA than during the placebo session for both touch speeds, indicating a relatively early influence within somatosensory pathways. Changes in OT levels showed an interaction with drug in an occipitotemporal region, area MT+, associated with motion perception. However, posterior insula did not show preferential activation for the slower stroking speed. These initial findings provide a basis for extending our knowledge of the neural processes underlying the effect of MDMA on affective touch.

Comparable studies

Other randomized controlled trials on MDMA, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Adults with moderate to severe post-traumatic stress disorder 2023 Randomized controlled trial n = 104

Citations in the library

Explore topics